Report Information More information from: https ://www.wis eguyreports .com/reports /495856
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Review, H1 2016 Report / Search Code: WGR495856
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) Pipeline Review, H1 2016’, provides in depth analys is on Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted pipeline therapeutics . The report provides comprehens ive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type
- The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) Overview 7 Therapeutics Development 8 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Stage of Development 8 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Therapy Area 9 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Indication 10 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Products under Development by Companies 13 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Therapeutics As s es s ment 15 As s es s ment by Monotherapy/Combination Products 15 As s es s ment by Mechanis m of Action 16 As s es s ment by Route of Adminis tration 18 As s es s ment by Molecule Type 20 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Companies Involved in Therapeutics Development 22 Alder Biopharmaceuticals Inc. 22 Ips en S.A. 23 Mallinckrodt Plc 24 Pfizer Inc. 25 Retrophin Inc. 26 XOMA Corporation 27 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Drug Profiles 28 ALD-1613 - Drug Profile 28 Product Des cription 28 Mechanis m Of Action 28 R& D Progres s 28 corticotropin - Drug Profile 29 Product Des cription 29 Mechanis m Of Action 29 R& D Progres s 29 cos yntropin - Drug Profile 31 Product Des cription 31
Mechanis m Of Action 31 R& D Progres s 31 Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cus hing’s Dis eas e - Drug Profile 32 Product Des cription 32 Mechanis m Of Action 32 R& D Progres s 32 Peptides to Antagonize ACTH Receptor for Cus hing's Syndrome - Drug Profile 33 Product Des cription 33 Mechanis m Of Action 33 R& D Progres s 33 Small Molecule to Antagonize Melanocortin Receptor 2 for Cus hing's Dis eas e and Congenital Adrenal Hyperplas ia - Drug Profile 34 Product Des cription 34 Mechanis m Of Action 34 R& D Progres s 34 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Dormant Projects 35 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Dis continued Products 36 Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or MC2R or ACTHR) - Featured News & Pres s Releas es 37 Apr 03, 2016: Alder Pres ents Preclinical Data for ALD1613 at ENDO 2016 37 Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Dis eas e Activity in Patients with Pers is tently Active Sys temic Lupus Erythematos us 37 Oct 13, 2015: Clinical Data on Mallinckrodt Pharmaceuticals ' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 39 Oct 08, 2015: Clinical Data on Mallinckrodt Pharmaceuticals ' H.P. Acthar Gel to be Unveiled at American College of Rheumatology 39 Mar 27, 2015: Pos itive Outcomes With H.P. Acthar Gel In Proteinuria In Nephrotic Syndrome Reported At National Kidney Foundation Spring Congres s 39 Jan 06, 2015: BioSim Pharmaceuticals to meet with Indus try during JP Morgan Healthcare Conference 40 May 05, 2014: Clinical Trial Res ults Indicate Acthar May Significantly Reduce Dis eas e Activity in Patients with Sys temic Lupus Erythematos us 41 Apr 21, 2014: Clinical Trial Res ults Indicate Acthar May Significantly Reduce Proteinuria in Patients with Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy 42 Oct 22, 2013: Ques tcor To Commence Phas e 2 Study of Acthar for Acute Res piratory Dis tres s Syndrome 43 Jul 24, 2013: Ques tcor to Commence Phas e 2 Study of Acthar for ALS 43 Jul 11, 2013: Ques tcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidos is 44 Jun 14, 2012: Ques tcor Pharma Announces Initial Commercialization Plans For Acthar Rheumatology Indications 45 Nov 10, 2011: New Res earch Sugges ts Ques tcor's Acthar Reduces Proteinuria In Idiopathic Membranous Nephropathy In Part Through Suppres s ion Of Anti-PLA2R Antibodies 46 Oct 15, 2010: Ques tcor Receives FDA Approval For H.P. Acthar Gel For Treatment Of Infantile Spas ms 46 Sep 08, 2010: Ques tcor Updates Status Of Supplemental New Drug Application For H.P. Acthar Gel 47 Appendix 48 Methodology 48 Coverage 48 Secondary Res earch 48 Primary Res earch 48 Expert Panel Validation 48 Contact Us 48 Dis claimer 49 Lis t of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 Number of Products under Development by Companies , H1 2016 13 Products under Development by Companies , H1 2016 14 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Stage and Mechanis m of Action, H1 2016 17 Number of Products by Stage and Route of Adminis tration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 21 Pipeline by Alder Biopharmaceuticals Inc., H1 2016 22 Pipeline by Ips en S.A., H1 2016 23 Pipeline by Mallinckrodt Plc, H1 2016 24 Pipeline by Pfizer Inc., H1 2016 25 Pipeline by Retrophin Inc., H1 2016 26 Pipeline by XOMA Corporation, H1 2016 27
Dormant Projects , H1 2016 35 Dis continued Products , H1 2016 36 Lis t of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Mechanis m of Actions , H1 2016 16 Number of Products by Stage and Mechanis m of Actions , H1 2016 16 Number of Products by Routes of Adminis tration, H1 2016 18 Number of Products by Stage and Routes of Adminis tration, H1 2016 18 Number of Products by Molecule Types , H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 20
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349